Leadership Overview
PCI Pharma Services has 7 executives leading key functions including information technology, finance, operations, and commercial packaging.
Driven by a commitment to advancing healthcare, PCI Pharma Services provides integrated, full-service solutions across the global pharmaceutical lifecycle, from development to commercialization.
Driven by a commitment to advancing healthcare, PCI Pharma Services provides integrated, full-service solutions across the global pharmaceutical lifecycle, from development to commercialization.
Leadership Roles at PCI Pharma Services
Tom De Weerdt - Chief Financial Officer
Tom De Weerdt, the Chief Financial Officer at PCI Pharma Services, manages all financial operations and strategic fiscal planning. Overseeing accounting, financial reporting, and capital allocation, De Weerdt ensures the financial health and stability of the organization across its United States and European locations. This critical role involves analyzing market trends and economic conditions to inform investment decisions and drive profitability. By guiding financial strategies, Tom De Weerdt supports the company's expansion and its integrated service model, which spans formulation development, clinical trial supply, and commercial manufacturing. The Chief Financial Officer's expertise is vital in maintaining investor confidence and securing resources for ongoing innovation and operational excellence, directly contributing to PCI Pharma Services' market leadership in the global healthcare industry.
Brad Payne - Chief Operating Officer
Brad Payne, the Chief Operating Officer at PCI Pharma Services, directs the operational execution of the company's integrated service offerings. Overseeing day-to-day activities across manufacturing, packaging, and supply chain management, Payne ensures seamless delivery of services to clients in the global healthcare industry. This leadership position involves optimizing production workflows and resource allocation within the United States and European facilities. By focusing on operational efficiency and quality control, Brad Payne supports the company's mission to provide comprehensive solutions, from clinical trial supply to commercial manufacturing. The Chief Operating Officer's strategic oversight guarantees that PCI Pharma Services maintains high standards of service and reliability, directly impacting client satisfaction and the company's competitive edge in pharmaceutical services.
Laila Rubi - Chief Operating Officer, Clinical Quality Documents
Laila Rubi, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, spearheads the management and integrity of all clinical quality documentation. Overseeing the meticulous creation, review, and archiving of essential documents, Rubi ensures compliance with stringent regulatory standards across the company's global operations. This specialized role is crucial for maintaining the quality and traceability of services provided, including formulation development and clinical trial supply. By implementing robust quality management systems, Laila Rubi guarantees that all documentation meets the highest industry benchmarks, supporting the company's reputation for excellence. The Chief Operating Officer, Clinical Quality Documents' dedication to precision directly underpins the reliability of PCI Pharma Services' offerings to the healthcare sector.
Halley Liu - President
Halley Liu, the President at PCI Pharma Services, provides overarching leadership and strategic direction for the organization. Guiding the company's vision and growth initiatives, Liu ensures alignment across all business units, including analytical services, formulation development, and commercial manufacturing. This executive position involves fostering a culture of innovation and operational excellence throughout the United States and European facilities. By setting high-level objectives and overseeing key strategic partnerships, Halley Liu drives the company's mission to serve the global healthcare industry effectively. The President's leadership is instrumental in maintaining PCI Pharma Services' position as a premier integrated service provider, directly contributing to its sustained success and market impact.
Yann Ghafourzadeh - President, Commercial Packaging Technology
Yann Ghafourzadeh, the President, Commercial Packaging Technology at PCI Pharma Services, leads the strategic development and execution of advanced commercial packaging solutions. Overseeing all aspects of packaging innovation, production, and quality control, Ghafourzadeh ensures that clients receive state-of-the-art packaging services that meet global regulatory requirements. This leadership role focuses on enhancing packaging efficiency, security, and patient compliance across the company's operations in the United States and Europe. By driving technological advancements in packaging, Yann Ghafourzadeh directly supports the commercialization of pharmaceutical products, ensuring their integrity from manufacturing to patient delivery. The President, Commercial Packaging Technology's expertise is vital for maintaining PCI Pharma Services' competitive advantage in delivering comprehensive supply chain solutions.
Brian Keesee - President, Clinical Trial Services
Brian Keesee, the President, Clinical Trial Services at PCI Pharma Services, directs the comprehensive suite of services supporting global clinical trials. Overseeing logistics, supply chain management, and specialized services for investigational medicinal products, Keesee ensures the seamless progression of clinical research for pharmaceutical clients. This critical role involves managing complex supply chains and ensuring adherence to strict timelines and quality standards across the United States and European operations. By optimizing the delivery of clinical trial materials, Brian Keesee directly enables the advancement of new therapies and treatments. The President, Clinical Trial Services' focus on operational excellence and client support solidifies PCI Pharma Services' position as a trusted partner in pharmaceutical development.
Edward DePrimo - Chief Information Officer
Edward DePrimo, the Chief Information Officer at PCI Pharma Services, directs all information technology strategy and execution. Overseeing the digital infrastructure, DePrimo ensures robust cybersecurity measures and seamless integration of systems across the company's global operations in the United States and Europe. This leadership role involves driving technological innovation to support the company's comprehensive service offerings, including analytical services, formulation development, and clinical trial supply. By optimizing data management and IT resources, Edward DePrimo enhances operational efficiency and supports the secure handling of sensitive client information, directly impacting the company's ability to deliver reliable pharmaceutical services. The Chief Information Officer's focus remains on leveraging technology to streamline processes and enable future growth within the healthcare industry.
Explore Leadership Teams in Manufacturing
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
USV Private Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. USV Limited was established in 1961.
Company Leadership SB
AM
SY
Gufic Group is a respected player in the pharmaceutical industry, established in 1970, known for its innovative and high-quality pharmaceutical and herbal products, along with a diverse range of APIs. They are recognized as one of India's largest manufacturers of lyophilized injections, offering a variety of products including antibiotics, antifungals, and antiviral treatments. Their extensive network facilitates the supply of these products to major hospital chains and leading medical facilities across India. Gufic is committed to research and development, continuously launching advanced new products while expanding their international footprint.
Company Leadership NY
SD
DR
Hemofarm is the leading pharmaceutical company in Serbia and in the region. Care for your health is the company's most important commitment. Hemofarm is a leader in the Serbian pharmaceutical market with a 17.3% share in financial terms. Holding a 79.1% share in the export of Serbian pharmaceutical products, the Vrac-based company is at the same time the leading Serbian exporter of medicinal products. Hemofarm produces over 4 billion tablets and capsules a year.
Company Leadership DS
DV
VA
TM
Frequently Asked Questions Regarding PCI Pharma Services Top Executives and Leadership Team
Unlock more people and company data
